Benefits of using vinpocetine in everyday practice – known indications and new perspectives of therapy Reprint from: Biblioteka Medycyny Faktów 1/2013
Article Sidebar
Published:
Dec 31, 2013
Keywords:
vinpocetine, mild cognitive impairments, dementia, stroke, dizziness
Main Article Content
Abstract
In the developed societies, nervous system diseases are among the most common and serious health problems. Advances in the biological sciences allowed us to know diseases ethiopathology and suggest new indications and prospects for drug therapy already in use. The use of vinpocetine in the treatment of various diseases is associated with various biological activities of this drug. Vinpocetine can be used with good effect in mild cognitive impairment, dementia syndromes, complications of stroke, headaches, dizziness, ear noise, encephalopathies and neuropathies of various etiologies.
Article Details
How to Cite
Banecka-Majkutewicz, Z. (2013). Benefits of using vinpocetine in everyday practice – known indications and new perspectives of therapy. Medycyna Faktow (J EBM), 6(4(21), 44-49. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2395
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Lorincz C., Szasz K., Kisfaludy L.: The synthesis of ethyl apovincaminate. Arzneimittelforschung 1976; 26: 1907.
2. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
3. Valikovics A.: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007; 60: 301-310.
4. Jeon K.I., Xu X., Aizawa T. et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
5. Matsukawa M., Ogawa M., Nakadate K. et al.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
6. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
7. Miyata N., Yamaura H., Tanaka M. et al.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
8. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
9. Feher G., Koltai K., Kesmarky G. et al.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
10. Szapáry L., Horváth B., Alexy T. et al.: Effect of vinpocetine on the hemorheologic parameters in patients with chronic cerebrovascular disease. Orv. Hetil. 2003; 144: 973-978.
11. Szakáll S., Boros I., Balkay L. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
12. Dodick D.W., Schwedt T.: Headache: challenging conventional wisdom. Lancet Neurol. 2009; 8: 12-4.
13. Colman I., Friedman B.W., Brown M.D. et al.: Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 1359-61.
14. Gabryel B., Adamek M., Pudelko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
15. Ribari O., Zelen B., Kollar B.: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung 1976; 26:1977-1980.
2. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
3. Valikovics A.: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007; 60: 301-310.
4. Jeon K.I., Xu X., Aizawa T. et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA 2010; 107: 9795-9800.
5. Matsukawa M., Ogawa M., Nakadate K. et al.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
6. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
7. Miyata N., Yamaura H., Tanaka M. et al.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
8. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-430.
9. Feher G., Koltai K., Kesmarky G. et al.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
10. Szapáry L., Horváth B., Alexy T. et al.: Effect of vinpocetine on the hemorheologic parameters in patients with chronic cerebrovascular disease. Orv. Hetil. 2003; 144: 973-978.
11. Szakáll S., Boros I., Balkay L. et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J. Neuroimaging. 1998; 8: 197-204.
12. Dodick D.W., Schwedt T.: Headache: challenging conventional wisdom. Lancet Neurol. 2009; 8: 12-4.
13. Colman I., Friedman B.W., Brown M.D. et al.: Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 1359-61.
14. Gabryel B., Adamek M., Pudelko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
15. Ribari O., Zelen B., Kollar B.: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung 1976; 26:1977-1980.